Episode 75 – Semaglutide in Obesity without Diabetes and Dapagliflozin in Heart Failure
Description
Welcome back Rounds Table Listeners!
We are back today with our Classic Rapid Fire Podcast!
This week, Drs. Mike and John Fralick discuss two recent papers exploring the role of semaglutide in patients with obesity without diabetes and the clinical implications of the decline in glomerular filtration rate after starting dapagliflozin in patients with heart failure. Two papers, here we go!
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (0:00 – 09:40 ).
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (09:40 – 19:24 ).
And for the Good Stuff:
How Ozempic and Weight Loss Drugs Are Reshaping Denmark’s Economy (19:24 – 19:58 ).
How a Canadian scientist and a venomous lizard helped pave the way for Ozempic (19:58 – 23:36 ).
Questions? Comments? Feedback? We’d love to hear from you! @roundstable
The post Episode 75 – Semaglutide in Obesity without Diabetes and Dapagliflozin in Heart Failure first appeared on Healthy Debate.
The post Episode 75 – Semaglutide in Obesity without Diabetes and Dapagliflozin in Heart Failure appeared first on Healthy Debate.
United States
